Skip to content

Author

G. Tortora

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Favezelimab/Pembrolizumab Coformulation Versus Standard-of-Care in PD-L1–Positive Metastatic Colorectal Cancer: The Phase III, Randomized KEYFORM-007 Study

The phase III KEYFORM-007 study (ClinicalTrials.gov identifier: NCT05064059 ) evaluated the efficacy and safety of coformulated favezelimab/pembrolizumab versus standard-of-care (SOC) in PD-L1–positive microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC). We present re...

N. Segal, Maria Passhak, F. Kose et al. · 0 citations
Review Open access Oct 2026

Antibiotics and outcomes of cancer immunotherapy: An updated meta-analysis and clinical applications.

The gut microbiome is a modifiable determinant of response to immune checkpoint inhibitors (ICI), positioning antibiotic exposure as a critical yet under-recognized risk factor for worse survival outcomes in immuno-oncology. As nearly 30% of ICI-treated patients receive antibiotics and indications of cancer immunothera...

Serena Porcari, L. Bolte, J. Björk et al. · 0 citations
Open access Sep 2026

Interobserver Agreement and Radiological-Pathological Concordance of CT Staging in Localized Colon Cancer.

BACKGROUND Accurate preoperative staging is essential for risk stratification and treatment planning in localized colon cancer (lCC), particularly in the context of emerging neoadjuvant strategies. However, the reproducibility of CT-based classification and its concordance with pathology remain incompletely defined....

Giovanni Trovato, M. Calegari, P. Testa et al. · 0 citations
Open access Sep 2026

Circulating tumor DNA tumor fraction as a biomarker in refractory metastatic colorectal cancer: findings from the CAVE-2 GOIM trial

Liquid biopsy guided anti-EGFR rechallenge therapy is gaining ground as a potential option for patient with refractory metastatic colorectal cancer. However, the identification of potential biomarkers to implement patient's stratification is required. The CAVE-2 GOIM trial investigated the role of rechallenge with cetu...

Davide Ciardiello, G. Martini, L. Boscolo Bielo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.